Archive

P53 status, and G2/M cell cycle arrest, are determining factors in cell-death induction mediated by ELF-EMF in glioblastoma.

This in vitro study tested ELF-EMF exposure in U87 and U251 glioblastoma cell lines and assessed apoptosis, cell-cycle distribution, cell size, and mRNA expression of cell-cycle genes. The authors report higher apoptosis induction and increased G2/M arrest in U87 compared with U251, alongside increased U87 cell size…

Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration.

This in vitro study evaluated whether extremely low-frequency EMF exposure (100 Hz, 100 G) modifies the effects of temozolomide (100 µM) in human glioblastoma U87 cells over 120–144 hours. The authors report that combined treatment reduced stemness-associated markers (Nestin, CD133, Notch4) and increased GFAP…

Extremely low frequency variable electromagnetic fields affect cancer and noncancerous cells in vitro differently: Preliminary study.

This in vitro study exposed cancer (U87-MG; 143B) and noncancerous (BJ; HEK) cells to extremely low frequency electromagnetic fields under varying frequencies (2–60 Hz), waveforms, and exposure durations, with sham controls. Cell viability was assessed using an MTT assay. The authors report that cancer and…

Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).

This in vitro study tested whether an extremely low-frequency EMF (100 Hz, 100 G) could enhance temozolomide cytotoxicity in human glioma cell lines (U87 and T98G). The authors report that combined EMF and temozolomide increased apoptosis relative to either treatment alone and was accompanied by changes in…